Castle Biosciences Stock Price, News & Analysis

Castle Biosciences (NASDAQ: CSTL) presented new data validating their DecisionDx-UM test and PRAME biomarker for uveal melanoma (UM) at the ARVO 2025 Annual Meeting. The study analyzed a real-world cohort of 1,297 patients with UM, validating findings from the COOG2.1 study.

The research confirms that combining PRAME gene expression information with DecisionDx-UM test results can better predict metastatic risk in UM patients. The study utilized data from the National Cancer Institute's SEER Program, demonstrating that co-reporting DecisionDx-UM class and PRAME status provides enhanced insights into metastasis likelihood, enabling more personalized treatment strategies for this rare but aggressive eye cancer.

Castle Biosciences (NASDAQ: CSTL) is commemorating Skin Cancer Awareness Month in May 2025 through various initiatives and partnerships. The company is sponsoring IMPACT Melanoma's virtual patient symposium "Melanoma Diagnosis: A Toolkit to Support the Journey" on May 21, featuring Dr. Aaron Farberg. Castle is also highlighting melanoma survivor Leah Adams' story, who benefited from their DecisionDx-Melanoma test for recurrence risk assessment.

The company continues partnerships with IMPACT Melanoma, AIM at Melanoma, and Melanoma Research Foundation, participating in advocacy walks nationwide. Additionally, Castle will be featured in USA TODAY's 2025 Skin Health Campaign, with an article titled "Transforming Skin Cancer and Melanoma Outcomes" appearing in the May 30 edition.

Castle Biosciences (CSTL) reported strong Q1 2025 results with revenue increasing 21% to $88 million compared to Q1 2024. The company delivered 24,402 total test reports, up 17% year-over-year. Core revenue drivers showed significant growth, with DecisionDx-Melanoma surpassing 200,000 test orders milestone. The company raised its 2025 revenue guidance to $287-297 million from $280-295 million. Notable metrics include DecisionDx-Melanoma (8,621 tests), DecisionDx-SCC (4,375 tests), and TissueCypher (7,432 tests). However, the company reported a net loss of $25.8 million and will discontinue its IDgenetix test offering in May 2025. Cash position remains strong at $275.2 million as of March 31, 2025.

Castle Biosciences (CSTL) has announced a definitive agreement to acquire Previse, a gastrointestinal health company specializing in chronic acid reflux related diseases and esophageal cancer. The acquisition aims to expand Castle's GI testing portfolio beyond their existing TissueCypher Barrett's Esophagus test. Previse's key assets include methylation technology developed at Johns Hopkins University School of Medicine and additional pipeline technologies. The deal, with undisclosed terms, is expected to close within weeks, subject to customary conditions. The acquisition aligns with Castle's strategy to enhance their gastroenterology franchise and address unmet needs in GI testing, including potential upstream opportunities.

Castle Biosciences (CSTL) will present new data on its TissueCypher Barrett's Esophagus test at the Digestive Disease Week (DDW 2025) Annual Meeting in San Diego from May 3-6. The company will showcase two key posters demonstrating TissueCypher's ability to identify patients with Barrett's esophagus who are at higher risk for developing esophageal cancer. A product theater featuring an expert physician panel will discuss clinical practice models for preventing progression from Barrett's to EAC. The presentations include research on the test's effectiveness in detecting missed neoplasia and providing risk stratification for Barrett's esophagus patients. Castle Biosciences will also participate in educational sessions in collaboration with GI experts and the American Society for Gastrointestinal Endoscopy (ASGE).

Castle Biosciences (Nasdaq: CSTL) has published a new study showing their DecisionDx-Melanoma test surpasses both AJCC staging and CP-GEP in identifying low-risk melanoma patients. The test achieved a 2.8% sentinel lymph node positivity rate, significantly below the NCCN guidelines' 5% threshold for avoiding sentinel lymph node biopsy (SLNB) surgery.

The study, published in Cancer Diagnosis & Prognosis, analyzed T1-T2 melanoma tumors across multiple validation studies. While patients classified as low risk by CP-GEP showed a 6.2% SLN positivity rate, DecisionDx-Melanoma demonstrated superior performance at 2.8%. This improvement is particularly significant as over 90% of T1-T2 tumor patients who undergo SLNB receive negative results.

The findings support using DecisionDx-Melanoma to guide SLNB decisions, especially for patients with thin tumors where surgical complications may outweigh benefits. The test provides personalized risk assessment for sentinel lymph node positivity and recurrence, enabling more informed melanoma management decisions.

Castle Biosciences (Nasdaq: CSTL) has announced reaching a significant milestone of over 200,000 DecisionDx-Melanoma clinical test orders. The DecisionDx-Melanoma is a 31-gene expression profile test designed for patients with stage I-III cutaneous melanoma.

The test provides personalized risk assessment by analyzing tumor biology and clinicopathologic features to predict recurrence risk, metastasis potential, and sentinel lymph node positivity. Its clinical value is validated by more than 50 peer-reviewed publications and studies involving over 10,000 patient samples, demonstrating association with improved patient survival.

Castle Biosciences (CSTL) presented new research data at the AACR Annual Meeting 2025 focusing on their DecisionDx tests for melanoma patients. The study of DecisionDx-Melanoma (n=1,661) showed that patients with Class 2B results had significantly higher distant metastasis rates compared to Class 1A across multiple sites: CNS (7.4% vs 0.9%), lung (7.4% vs 1.2%), liver (4.5% vs 0.6%), and bone (3.0% vs 0.8%).

Additionally, research on DecisionDx-UM for uveal melanoma revealed that among 79 patients, 72% were classified as low risk (Class 1) and 28% as high risk for metastasis. The study identified significant protein differences in aqueous humor samples between risk classes (N=386, p<0.0001), potentially enabling earlier detection and intervention for uveal melanocytic tumors.

Castle Biosciences (CSTL) has scheduled the release of its first quarter 2025 financial results for Monday, May 5, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern time to discuss the results.

The live webcast will be accessible through the company's investor relations website and a dedicated event link. Participants can join via phone by dialing 1 833 470 1428 from the United States using access code 040892. International dial-in numbers are available. A Q&A session will follow management's presentation, and a webcast replay will be provided after the call.